Affymax’s Omontys Recalled After Deaths; Uncertain Future Ahead For Company
This article was originally published in The Pink Sheet Daily
Executive Summary
Affymax and its partner Takeda recalled all of their ESA product after rare but unexplained patient fatalities, leaving both the product’s and the company’s future in limbo. The safety concerns may fuel fears about the unknowns of biologic production.